Global CDMO FIS is a growing international CDMO with multiple European sites and a commercial presence in the USA, Japan, China and India, presenting cross-border collaboration opportunities for expansion, new client onboarding, and co-development projects.

Strong R&D With over 250 R&D specialists and capabilities spanning optimization, scale-up, and large-scale production, FIS can offer end-to-end development solutions that appeal to pharma companies seeking risk-reduced transitions from development to manufacturing.

Private Equity Backing Controlled by Bain Capital, FIS benefits from potential strategic investments, growth capital, and partnership opportunities to accelerate capacity expansion, technology upgrades, and new market entry initiatives.

Quality and Safety A core focus on integrity, safety, product quality, and people’s well-being signals reliability and compliance credibility, which can be leveraged when selling to manufacturers prioritizing GMP, regulatory readiness, and supplier stability.

Sustainability & Partnerships Emphasis on responsible and sustainable operations creates a selling angle for customers seeking ethical supply chains, ESG-aligned suppliers, and long-term, value-driven collaborations in the pharmaceutical ingredients space.